First author [ref.] | Comparator | Patients n | Duration weeks | Baseline FEV1 L | Exacerbations | Associated hospitalisations |
Casaburi [9] | Placebo | 921 | 52 | 1.02 | ↓ | ↓ |
Vincken [10] | Ipratropium | 535 | 52 | 1.25 | ↓ | ↓ |
Brusasco [11] | Placebo | 1207 | 26 | 1.12 | ↓ | NS |
Brusasco [11] | Salmeterol | 1207 | 26 | 1.12 | NS | NS |
Niewoehner [12] | Placebo | 1829 | 26 | 1.04 | ↓ | ↓ |
Dusser [13] | Placebo | 1010 | 52 | 1.37 | ↓ | NS |
↓: significant reduction in exacerbation or associated hospitalisation end-points versus comparator; NS: no significant reduction in exacerbation or associated hospitalisation end-points versus comparator.